同行评议与多轮人工复核流程。针对直接服务临床决策支持的重要内容，引入同行评议和多轮人工复核 流程，重点关注安全边界、禁忌事项和高风险场景，确保内容符合当前医疗行业的专业共识和质量要 求。 近日，中央网信办旗下杂志《中国网信》刊发了丁香园创始人、董事长李天天的署名文章：以 "负责任 创新" 探索医疗人工智能发展新路径。文章提到了丁香园在医疗人工智能领域秉持 "负责任创新" 理 念，在医疗AI产品的研发上以数据质量为优先，坚持 "有错必纠"，强化风险提示与循证依据前置，减 少低级错误发生的概率，谨慎推进医疗人工智能的应用实践。以下为文章全文： 近年来，人工智能技术在医疗健康领域的应用不断深化，从医学知识检索、辅助诊疗到科研支持与健康 管理，展现出广阔前景。与此同时，算法偏差、数据质量、责任边界等问题也逐渐显现。如何在鼓励技 术创新的同时，有效防范潜在风险，推动人工智能在医疗健康领域实现风险可控、结论可信、发展可持 续，成为当前亟须回应的重要课题。在这一背景下，"负责任创新" 逐渐成为行业发展共识。在医疗健 康等高风险领域，更应坚持审慎原则，将安全性、有效性和合规性置于优先位置。 以数据质量为核心的技术路径选择 医 ...

Core Viewpoint - The article discusses the development of AMIE, an AI system designed to assist in complex cardiology care, addressing the shortage of specialized medical professionals and improving diagnostic accuracy and efficiency [3][7][16]. Group 1: Challenges in Cardiology - There is a significant shortage of specialized medical knowledge in cardiology, leading to challenges in providing timely and effective medical services [2]. - The World Health Organization (WHO) predicts a global shortage of 18 million healthcare workers by 2030, with cardiology being particularly affected [5]. - In the U.S., over half of the states lack specialized centers for hypertrophic cardiomyopathy, resulting in 60% of patients not receiving a diagnosis [5]. Group 2: AMIE Development and Functionality - AMIE (Articulate Medical Intelligence Explorer) is an experimental AI system based on the Gemini 2.0 Flash large language model, specifically designed for complex cardiology cases [7][8]. - Unlike traditional AI systems, AMIE can analyze multiple diagnostic tests, including ECG, echocardiograms, and cardiac MRIs, providing comprehensive diagnostic suggestions [8]. Group 3: Clinical Trial Design and Results - The study utilized a randomized controlled trial design, selecting clinical data from 107 real patients with various complex heart conditions [10]. - Nine cardiologists were divided into two groups: one using AMIE for diagnostic assistance and the other relying solely on personal experience [11]. - Results showed that cardiologists preferred the diagnoses assisted by AMIE, with a preference rate of 46.7% compared to 32.7% for those relying on personal experience [15]. Group 4: Impact on Diagnostic Quality and Efficiency - AMIE significantly reduced clinical errors, with a notable decrease in significant errors (13.1% vs 24.3%) and important omissions (17.8% vs 37.4%) [15]. - The use of AMIE improved clinical assessments in 57% of cases and saved time in 50.5% of cases, enhancing doctors' confidence in their decisions [15]. Group 5: Future Implications of AMIE - AMIE excels in management plan formulation and diagnostic test recommendations, providing detailed information on rare diseases and prompting critical thinking [16]. - The study highlights the potential for AI to enhance human expertise in specialized medical fields, particularly in areas with a shortage of specialists [16]. - This research marks a significant step for AI in specialized healthcare, indicating a future direction of human-AI collaboration for improved patient care [16].

Group 1 - The core viewpoint of the article is the signing of a cooperation framework agreement between Henan Provincial People's Hospital and Huawei, aimed at enhancing medical services through digital transformation and artificial intelligence [1][3] Group 2 - The collaboration will leverage the strengths of both parties in areas such as medical artificial intelligence and digital talent cultivation, accelerating the digitalization of healthcare services [3] - The agreement aligns with national requirements for information technology innovation and responds to the demand for innovation in the healthcare sector [3] - Huawei aims to utilize its ICT technology advantages to support the digital transformation of Henan Provincial People's Hospital, with a focus on creating a leading smart hospital model in Henan [3]

来源：直通IPO，文/韩文静 2月6日，卓正医疗在港交所挂牌上市，此次发行价为59港元/股，开盘涨37.3%至81港元/股，总市值52.86亿港元。截至当日收盘，卓正医疗每股涨13.36%至 67.9港元，总市值43.72亿。 卓正医疗由王志远创立，定位于中高端医疗服务市场的私立医疗机构。卓正医疗在招股书中称，其目标客群是具有较强购买力及偏好更个性化护理的大众富 裕人群，即人均年可支配收入超过20万元的群体。 2012年，卓正医疗通过在深圳的首家建筑面积约50平方米的诊所开展门诊服务。2015年，公司通过在广州及北京成立首批门诊，扩大地理覆盖范围。2018 年，公司成立首家建筑面积超过1000平方米且拥有超过五个科室的医疗服务机构。2021年，公司在新加坡成立首家海外诊所。 | 今井 | 81.000 | | 最高 | 90.850 | | 成交量 | | --- | --- | --- | --- | --- | --- | --- | | 昨收 | 59.900 | | 最低 | 65.150 | | 成交额 | | 换手率 | 3.75% | | 市盈(TTM) | 34.44 | | 总市值 | | ...

Core Viewpoint -卓正医疗控股有限公司 (卓正医疗) successfully listed on the Hong Kong Stock Exchange, closing at HKD 67.90, a 13.36% increase from its final offering price of HKD 59.90 [1][6]. Group 1: Offering Details - The total number of shares offered globally was 4,750,000, with 475,000 shares allocated for public offering in Hong Kong and 4,275,000 shares for international offering [2]. - The total proceeds from the offering amounted to HKD 284.53 million, with net proceeds after estimated listing expenses of HKD 208.86 million [6][5]. Group 2: Use of Proceeds - The net proceeds will be used to build a professional talent pool for medical AI applications, enhance internal IT systems, upgrade existing medical facilities, establish new ones, and acquire well-performing medical institutions in major cities [6][7]. Group 3: Business Overview - 卓正医疗 operates 19 medical service institutions in China and four general practice clinics in Singapore, focusing on private healthcare services [7]. - Revenue projections for the years ending December 31 are as follows: RMB 473.2 million in 2022, RMB 690.4 million in 2023, and RMB 958.6 million in 2024, with net losses of RMB -221.5 million, -353.2 million, and a projected profit of RMB 80.2 million in 2024 [7][8]. Group 4: Financial Performance - Adjusted net losses for 2022 and 2023 were RMB 123.0 million and RMB 43.6 million, respectively, while adjusted net profits are projected for 2024 and the first eight months of 2025 [10][11]. - Operating cash flows for the years ending December 31 are projected to be RMB 6.9 million in 2022, RMB 123.8 million in 2023, and RMB 171.3 million in 2024 [12]. Group 5: Debt and Financial Challenges - As of the end of 2024, 卓正医疗's total liabilities reached RMB 30.85 billion, with current liabilities increasing from RMB 22.62 billion in 2022 to RMB 27.04 billion by August 2025 [13].

Transaction Overview - The company plans to acquire 38% equity of Boke Guoxin (Wuhan) Technology Co., Ltd. for a total consideration of RMB 73.71 million, distributed among four sellers [2][4][17] - After the transaction, the company's ownership in the target company will increase from 32% to 70%, making it a subsidiary included in the consolidated financial statements [2][4][36] - This acquisition is a strategic move to enhance the company's capabilities in automation hardware, software platforms, and medical AI applications, promoting a comprehensive integration of products and solutions [4][5][35] Financial Details - The target company achieved an unaudited net profit of RMB 14.33 million in 2025, leading to an overall valuation of RMB 194 million based on a price-to-earnings (PE) ratio of 13.54 [12][15] - The acquisition price reflects a significant premium over the target company's net assets, with a net asset appreciation rate of 200.13% [15][36] Strategic Implications - The acquisition is expected to enhance the company's market competitiveness by integrating its existing products with the target company's AI solutions, thereby creating a more comprehensive smart hospital solution [5][35] - The target company is a member of the China Healthcare Information Interoperability Technology Alliance and has experience with international healthcare standards, which will aid in expanding the company's overseas market presence [5][35] Approval and Compliance - The transaction was approved by the company's board on February 5, 2026, and does not require shareholder approval as it does not constitute a related party transaction or a major asset restructuring [3][6][35] - The transaction is subject to various regulatory approvals and the signing of a share transfer agreement, which has not yet occurred [3][6][35] Management and Operational Changes - Post-acquisition, the target company's board will be restructured, with the company's representatives holding a majority of the board seats, and the chairman will be the company's actual controller [37][36] - The transaction does not involve any personnel changes or land leasing issues within the target company [37][36]

Core Viewpoint - The company, Jianhui Information, plans to acquire additional equity in Boke Guoxin (Wuhan) Technology Co., Ltd., increasing its ownership from 32% to 70%, thereby making it a subsidiary and consolidating it into the company's financial statements [1] Group 1: Acquisition Details - Jianhui Information will purchase 16.75%, 13.25%, 4%, and 4% equity stakes from four entities for a total of 37.687 million yuan [1] - Post-transaction, the remaining 30% of Boke Guoxin will be held by Zhou Xiaoping [1] Group 2: Strategic Implications - This acquisition is a key move for the company to implement its intelligent development strategy and enhance industry chain collaboration [1] - The increased stake will allow for better integration of technology advantages in automation hardware, software platforms, and medical AI [1] - The collaboration aims to create a more competitive overall solution for smart hospitals and regional healthcare [1]

Core Viewpoint - The company, Jianhui Information, is acquiring additional equity in Boke Guoxin (Wuhan) Technology Co., Ltd., increasing its ownership from 32% to 70%, which will make Boke Guoxin a subsidiary and included in the consolidated financial statements [1] Group 1: Transaction Details - The company plans to acquire 16.75%, 13.25%, 4.00%, and 4.00% equity stakes from Zhou Xiaoping, Ze Pu Investment, Boke Yixin, and Boke Guoxin for a total of RMB 37.6875 million, 22.8563 million, 6.375 million, and 6.7914 million respectively [1] - After the transaction, Zhou Xiaoping will hold the remaining 30% of Boke Guoxin [1] Group 2: Strategic Importance - This transaction is a key measure for the company to implement its intelligent development strategy and deepen industry chain collaboration [1] - Increasing the stake in Boke Guoxin will facilitate the integration of both parties' technological advantages in automation hardware, software platforms, and medical AI [1] Group 3: Market Expansion and Innovation - Boke Guoxin is a member of the China Healthcare Information Interconnection Technology Alliance and has extensive development experience with the HL7 international medical information standards, which will aid the company's overseas market expansion [2] - The acquisition will accelerate the company's business development in emerging markets such as county-level medical communities and data governance for medical institutions [2] - The integration of business and resource sharing is expected to enhance the company's technological innovation capabilities and market responsiveness, laying a solid foundation for future performance growth [2]

山东大学齐鲁医院院长陈玉国认为，当前人工智能的快速发展，正深刻重塑医疗行业。如何适配临床需 求，兼顾安全性和创新性的医疗AI的生态，已经成为当前医院高质量发展的必答题。医疗人工智能的 协同创新发展，不仅仅是突破行业发展的桎梏，激发高质量发展新动能的关键支撑，更是拓宽医疗服务 覆盖面，加快实现健康普惠的重要抓手。期待各方同道共同深化合作凝聚共识和力量，携手推动我国医 疗人工智能迈向更加规范、安全、高质量的发展新阶段。 会上，为持续推动医疗AI普惠发展，华为重磅智慧病理云边端解决方案，并与上海交通大学医学院附 属瑞金医院(以下简称"瑞金医院")联合发布RuiPath智慧病理一体机——FusionCube A1000、FusionCube E200，助力基层医院快速部署AI病理模型，提升诊断能力，推动医疗资源均衡化。据了解，尽管AI辅 助病理诊断技术日益成熟，但基层医院仍面临智慧化建设成本高、AI应用部署周期长、辅助诊断精度 提升慢等现实难题，这些问题已成为医疗AI普惠化落地的主要瓶颈。为此，华为整合ICT及云领域核心 技术推出智慧病理云边端解决方案，将三甲医院高水平的AI辅助病理诊断能力快速下沉至基层医院。 华为 ...

如今，科创中心回归城市中心已经成为全球趋势。市政协常委娄永琪呼吁要把握重要契机。"上海 每个区都有各自特点，每所高校也各有所长。如果我们把区域与学校进行不同排列组合，那么上海有望 出现更多创新范式。"娄永琪建议，复兴岛可以作为试点，在这里推出更多应用系列场景，构建出未来 城市实验区、创新创业和人才集聚区、时空智能创新先行区。 本次市人代会的一大亮点，是"十五五"规划草案将提交代表审查和大会表决。此前，人大代表们已 围绕"十五五"民生改善主题深入社区，与居民面对面交流，收集意见建议5400余条。记者获悉，不少代 表将继续就规划的具体内容与实施路径建言献策，推动"十五五"蓝图更贴近民意、更符合实际。 "医疗人工智能的精准性与专业性，离不开海量、高质量健康医疗数据。"今年两会，市人大代表姚 海嵩准备就"以智慧医学赋能民生健康"领域建言，他认为，要加大大健康医疗数据的开放共享力度，同 时加快推进相关立法进程，建立健全数据安全与保护的规范体系，让健康保障更有力、更贴心。 去年，46岁的单身女性蒋女士因病离世，掀起社会对意定监护及遗产管理问题的讨论。市政协委员 张玉霞认为，这一案例突出体现了临时监护落地难的问题。"在法定 ...